Stay updated with breaking news from Lawrence Eichenfield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This segment of Dr. Eichenfield’s interview featured a discussion about Eichenfield’s response to the FDA’s approval of cantharadin 0.7%, or VP-102, for molluscum contagiosum.
:max_bytes(150000):strip_icc()/GettyImages-1036030724-114b5f1ec5bf420fbec406d8be06c5fb.jpg)
Acne on a baby's face is a common occurrence for many young children. Find out what causes baby acne and how to treat it.
A therapy has reached the pediatric vitiligo market—and more are on the way. Dermatologists Raj Chovatiya, MD, PhD, and Lawrence Eichenfield, MD, review the major shifts in pediatric vitiligo care and pharmacotherapy developments live from the Revolutionizing Atopic Dermatitis 2023 Annual Meeting in Washington, DC.
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician contributors, and more.
Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.